The psychedelics company said its total assets as at June 20, 2020 came in at US$29.8 million, including the $24 million in cash, which will be used primarily to advance its multiple clinical trials on psychedelic substances like LSD, DMT and MDMA.
New York-based MindMed is aiming to make psychedelic medicines available to patients who suffer from mental health disorders, cluster headaches and substance abuse.
In June, MindMed announced it is collaborating on a study examining DMT, a naturally-occurring psychedelic substance that causes a rapid onset and offset of action compared to similar psychedelic substances like psilocybin or LSD. The firm is working with its Swiss research partner to evaluate the effect of the ayahuasca-derived substance in humans.
In addition, the company officially launched Project Lucy, a commercial drug development program for the treatment of anxiety disorders and the first experiential, psychedelic-assisted therapy to be added to its drug development pipeline.
The firm also filed two separate patent applications for technologies that will screen and optimize the dosing of MDMA and LSD.
The company's net loss for the three-month period ended June 30, 2020 came in at $5.6 million.
Shares of MindMed climbed 2% higher in Canada at C$0.52 and 2.2% higher over the counter at US$0.39 on Friday morning.
Contact Angela at email@example.com
Follow her on Twitter @AHarmantas